Related content

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes

By Hanefeld Markolf   Herman Gary A.   Wu Mei   Mickel Carolyn   Sanchez Matilde   Stein Peter P.    

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1329-1339

Informa Healthcare

Access to resources Recommend Favorite

Saxagliptin: a New DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

By Tahrani Abd   Piya Milan   Barnett Anthony  

Advances in Therapy, Vol. 26, Iss. 7, 2009-07 ,pp. : 736-736

Springer Publishing Company

Access to resources Recommend Favorite

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

By Herman Gary A.   Bergman Arthur   Yi Bingming   Kipnes Mark    

Current Medical Research and Opinion, Vol. 22, Iss. 10, 2006-10 ,pp. : 1939-1947

Informa Healthcare

Access to resources Recommend Favorite

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes

By Pratley Richard E.   Salsali Afshin  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 919-931

Informa Healthcare

Access to resources Recommend Favorite

Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta‐analysis of randomized controlled clinical trials

By  

CLINICAL ENDOCRINOLOGY, Vol. 83, Iss. 3, 2015-09 ,pp. : 344-351

John Wiley & Sons Inc

Access to resources Recommend Favorite